

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI715410

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
Apeiron Biologics GmbH	12/20/2024

RECEIVING PARTY DATA

Company Name:	Citibank, N.A., as Administrative Agent
Street Address:	6400 Las Colinas Blvd., Mail Stop CC1-30
City:	Irving
State/Country:	TEXAS
Postal Code:	75039

PROPERTY NUMBERS Total: 16

Property Type	Number
Patent Number:	9777068
Patent Number:	11447565
Patent Number:	10294305
Patent Number:	10995147
Patent Number:	9840566
Patent Number:	11597775
Patent Number:	11492412
Patent Number:	10716833
Patent Number:	8586319
Patent Number:	9186373
Patent Number:	9757433
Patent Number:	9561263
Patent Number:	8946162
Patent Number:	10472341
Application Number:	17933295
Application Number:	18178778

CORRESPONDENCE DATA

Fax Number: 7043738822

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

PATENT

Phone: 7043734640
Email: bsmith@mcguirewoods.com
Correspondent Name: Betty G Smith, Senior Paralegal
Address Line 1: McGuireWoods LLP, 201 N. Tryon St.
Address Line 2: Suite 3000
Address Line 4: Charlotte, NORTH CAROLINA 28202

ATTORNEY DOCKET NUMBER: 5040387-0147

NAME OF SUBMITTER: Betty Smith

SIGNATURE: Betty Smith

DATE SIGNED: 12/23/2024

Total Attachments: 4

source=Notice of Grant of Security Interests in Patents - Apeiron Biologics GmbH (12.20.2024)#page1.tiff

source=Notice of Grant of Security Interests in Patents - Apeiron Biologics GmbH (12.20.2024)#page2.tiff

source=Notice of Grant of Security Interests in Patents - Apeiron Biologics GmbH (12.20.2024)#page3.tiff

source=Notice of Grant of Security Interests in Patents - Apeiron Biologics GmbH (12.20.2024)#page4.tiff

NOTICE
OF
GRANT OF SECURITY INTEREST
IN
PATENTS

Dated December 20, 2024

United States Patent and Trademark Office

Ladies and Gentlemen:

Please be advised that pursuant to the Security and Pledge Agreement dated as of October 12, 2023 (as amended, modified, extended, restated, renewed, replaced, or supplemented from time to time, the "Agreement") by and among the Grantors party thereto (each a "Grantor" and collectively, the "Grantors") and Citibank, N.A., as administrative agent (the "Administrative Agent") for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in, and a right to set off against, the patents and patent applications shown on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties.

The undersigned Grantor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the foregoing patents and patent applications (a) may only be terminated in accordance with the terms of the Agreement and (b) is not to be construed as an assignment of any patent or patent application.

[SIGNATURE PAGES TO FOLLOW]

APEIRON BIOLOGICS GMBH

By: Paul J. Hadden
Name: Paul Hadden
Title: Authorized Signatory

Acknowledged and Accepted:

CITIBANK, N.A., as Administrative Agent

By: *Laura Fogarty*
Name: Laura Fogarty
Title: Vice President

SCHEDULE 1**PATENTS**

Patent/Publ.	Application No.	Title	Assignee
9,777,068	14/409,161	METHOD FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
US2023/0340148	17/933,295	METHOD FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
11,447,565	15/700,538	METHOD FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
10,294,305	14/182,776	METHOD FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
10,995,147	16/920,880	PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
9,840,566	15/036,519	PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
11,597,775	15/824,055	PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
11,492,412	17/190,792	PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
US2024/0158530	18/178,778	PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER	APEIRON Biologics GmbH
10,716,833	15/833,243	METHOD FOR PRODUCING ACE2 POLYPEPTIDE	APEIRON Biologics GmbH
8,586,319	12/664,641	RECOMBINANT ACE2 POLYPEPTIDE DIMER	APEIRON Biologics GmbH
9,186,373	13/977,453	SIRNA AGAINST CBL-B AND OPTIONALLY IL-2 AND IL-12 FOR USE IN THE TREATMENT OF CANCER	APEIRON Biologics GmbH
9,757,433	14/760,529	MODIFIED ACE2 POLYPEPTIDES	APEIRON Biologics GmbH
9,561,263	12/808,818	TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2	APEIRON Biologics GmbH
8,946,162	12/937,029	TREATMENT OF TUMORS	APEIRON Biologics GmbH
10,472,341	15/554,354	BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES	APEIRON Biologics GmbH

PATENT**RECORDED: 12/23/2024****REEL: 069669 FRAME: 0913**